167 related articles for article (PubMed ID: 20953648)
21. Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
Saxena S; Samala G; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 Apr; 23(7):1402-12. PubMed ID: 25766629
[TBL] [Abstract][Full Text] [Related]
22. Novel anti-tubercular and antibacterial based benzosuberone-thiazole moieties: Synthesis, molecular docking analysis, DNA gyrase supercoiling and ATPase activity.
Omar MA; Masaret GS; Abbas EMH; Abdel-Aziz MM; Harras MF; Farghaly TA
Bioorg Chem; 2020 Nov; 104():104316. PubMed ID: 33022549
[TBL] [Abstract][Full Text] [Related]
23. Molecular Modeling Studies of Novel Fluoroquinolone Molecules.
Allaka TR; Katari NK; Veeramreddy V; Anireddy JS
Curr Drug Discov Technol; 2018; 15(2):109-122. PubMed ID: 28875852
[TBL] [Abstract][Full Text] [Related]
24. Mycobacterial DNA gyrB inhibitors: Ligand based pharmacophore modelling and in vitro enzyme inhibition studies.
Saxena S; Renuka J; Jeankumar VU; Yogeeswari P; Sriram D
Curr Top Med Chem; 2014; 14(17):1990-2005. PubMed ID: 25262795
[TBL] [Abstract][Full Text] [Related]
25. De novo design of novel DNA-gyrase inhibitors based on 2D molecular fingerprints.
Huang Z; Lin K; You Q
Bioorg Med Chem Lett; 2013 Jul; 23(14):4166-71. PubMed ID: 23743285
[TBL] [Abstract][Full Text] [Related]
26. In silico assessment of adverse effects of a large set of 6-fluoroquinolones obtained from a study of tuberculosis chemotherapy.
Tusar M; Minovski N; Fjodorova N; Novic M
Curr Drug Saf; 2012 Sep; 7(4):313-20. PubMed ID: 23062244
[TBL] [Abstract][Full Text] [Related]
27. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
[TBL] [Abstract][Full Text] [Related]
28. Combined QSAR/QSPR and molecular docking study on fluoroquinolones to reduce biological enrichment.
Zhao X; Zhao Y; Ren Z; Li Y
Comput Biol Chem; 2019 Apr; 79():177-184. PubMed ID: 30836319
[TBL] [Abstract][Full Text] [Related]
29. Pharmacophore modeling and molecular dynamics approach to identify putative DNA Gyrase B inhibitors for resistant tuberculosis.
Kashyap A; Singh PK; Satpati S; Verma H; Silakari O
J Cell Biochem; 2019 Mar; 120(3):3149-3159. PubMed ID: 30191589
[TBL] [Abstract][Full Text] [Related]
30. Design of (quinolin-4-ylthio)carboxylic acids as new Escherichia coli DNA gyrase B inhibitors: machine learning studies, molecular docking, synthesis and biological testing.
Metelytsia L; Hodyna D; Dobrodub I; Semenyuta I; Zavhorodnii M; Blagodatny V; Kovalishyn V; Brazhko O
Comput Biol Chem; 2020 Apr; 85():107224. PubMed ID: 32018168
[TBL] [Abstract][Full Text] [Related]
31. Assessment of Structural Basis for Thiazolopyridine Derivatives as DNA Gyrase-B Inhibitors.
Zambre VP; Petkar NN; Dewoolkar VP; Bhadke SV; Sawant SD
Curr Drug Discov Technol; 2023; 20(4):e220223213933. PubMed ID: 36815634
[TBL] [Abstract][Full Text] [Related]
32. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase.
Sriram D; Aubry A; Yogeeswari P; Fisher LM
Bioorg Med Chem Lett; 2006 Jun; 16(11):2982-5. PubMed ID: 16554151
[TBL] [Abstract][Full Text] [Related]
33. Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling.
Jeankumar VU; Reshma RS; Janupally R; Saxena S; Sridevi JP; Medapi B; Kulkarni P; Yogeeswari P; Sriram D
Org Biomol Chem; 2015 Feb; 13(8):2423-31. PubMed ID: 25569565
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
Ventura C; Latino DA; Martins F
Eur J Med Chem; 2013; 70():831-45. PubMed ID: 24246731
[TBL] [Abstract][Full Text] [Related]
35. Discovery of new
Mehra R; Chib R; Munagala G; Yempalla KR; Khan IA; Singh PP; Khan FG; Nargotra A
Mol Divers; 2015 Nov; 19(4):1003-19. PubMed ID: 26232029
[TBL] [Abstract][Full Text] [Related]
36. Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update.
Das S; Garg T; Srinivas N; Dasgupta A; Chopra S
Curr Top Med Chem; 2019; 19(8):579-593. PubMed ID: 30834837
[TBL] [Abstract][Full Text] [Related]
37. Virtual Screening of potential drug-like inhibitors against Lysine/DAP pathway of Mycobacterium tuberculosis.
Garg A; Tewari R; Raghava GP
BMC Bioinformatics; 2010 Jan; 11 Suppl 1(Suppl 1):S53. PubMed ID: 20122228
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons.
Gibson EG; Blower TR; Cacho M; Bax B; Berger JM; Osheroff N
ACS Infect Dis; 2018 Aug; 4(8):1211-1222. PubMed ID: 29746087
[TBL] [Abstract][Full Text] [Related]
39. QSAR based therapeutic management of M. tuberculosis.
Ahamad S; Rahman S; Khan FI; Dwivedi N; Ali S; Kim J; Imtaiyaz Hassan M
Arch Pharm Res; 2017 Jun; 40(6):676-694. PubMed ID: 28456911
[TBL] [Abstract][Full Text] [Related]
40. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
Chaudhari K; Surana S; Jain P; Patel HM
Eur J Med Chem; 2016 Nov; 124():160-185. PubMed ID: 27569197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
